Camlin Fine Sciences has received approval for strategic investment in AlgalR NutraPharms (AlgalR) by way of acquisition of equity shares amounting to 69.33% of the existing paid?up share capital (Secondary Purchase). The Committee has also approved subscription to the equity shares of AlgalR (Primary Subscription). Upon consummation of the Secondary Purchase and Primary Subscription, the Company will hold 80% of the paid?up capital of AlgalR on a fully diluted basis. The Company will now be executing the Investment Agreement, Share Purchase Agreement and the incidental agreements / documents with AlgalR and its promoters / other shareholders.
AlgalR provides an opportunity to the Company for expanding its footprint into the Nutraceuticals segment. Upon completion of the acquisition, the Company shall become the holder of 80% of the paid? up share capital of AlgalR on a fully diluted basis.
Camlin Fine Sciences is the world's second largest manufacturer and marketer of food grade antioxidants BHA (butylated hydroxyanisole) and TBHQ (Tertiary Butylhydroquinone).
| Company Name | CMP |
|---|---|
| BASF India | 3808.00 |
| Tata Chemicals | 813.25 |
| SRF | 2719.75 |
| Pidilite Inds. | 1422.20 |
| Deepak Nitrite | 1819.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: